Single Ascending Dose Study of AMG 570 in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Systemic Lupus Erythematosus

In brief

The purpose of this study is to obtain initial information on the safety and tolerability (effects good or bad), pharmacokinetics (what the body does to the drug), and pharmacodynamics (what the drug does to the body) of a single dose of AMG 570.

Key facts

Study ID

NCT02618967

Run by

Amgen

People needed

56

Starts

2016-03-28

Expected to finish

2018-12-03

Last updated by the study team

2024-05-14

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy as determined by the investigator
• Normal or clinically acceptable electrocardiogram (ECG)
• Female subjects must be of documented non-reproductive potential
• Subjects must be current for all vaccinations
• Other inclusion criteria may apply

You may not qualify if…

• Current or chronic history of liver disease
• History of active infections
• History of significant respiratory disorder
• Evidence of renal disease
• Other exclusion criteria may apply

Where it is running

• Research Site — Evansville, Indiana, United States
• Research Site — Overland Park, Kansas, United States
• Research Site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.